"Like any antimicrobial drug, those that are now on the market will become less and less effective as resistant forms of herpes simplex begin to emerge," said John J. Docherty, Ph.D., professor and chairperson, Department of Microbiology and Immunology at NEOUCOM.
"For this reason, it is very important to have new products ready to replace the ones that currently are being used."Docherty
has discovered that resveratrol shows promise in effectively treating and preventing the spread of herpes simplex virus (HSV).A patent was recently issued for a resveratrol-based compound that could be used for effective treatment of HSV.The compound has shown such promise that Royalmount Pharmaceuticals, Inc.
, of Montreal, Quebec, Canada, inked a cooperative research and development agreement and a patent licensing agreement with Docherty
.In the research agreement, Docherty
receives a continuing grant to study the inhibition of herpes simplex by resveratrol.
Another resveratrol-containing compound: Resvert
According to Docherty
, new herpes drugs are especially important if the number of people infected by the disease is taken into consideration.Most adults have some type of herpes, usually in the oral form of the disease which is caused by HSV-1.HSV-2, the sexually transmitted disease form, affects approximately 23 percent of the American population and many thousands of new cases are reported each year.A typical treatment can cost more than $220, and the market for drug treatment is approximately $4 billion per year.Docherty has been a professor and chairperson of NEOUCOM's Department of Microbiology and Immunology for 15 years.Previously he spent 14 years as a faculty member at Penn State University.
...A native of Youngstown, Ohio, Docherty earned a bachelor's degree from Youngstown State University, a master's degree from Miami University of Ohio and a doctorate from the University of Arizona, Tucson.He
performed a postdoctoral fellowship in virology at The Pennsylvania State University Medical School, Hershey